Jeffrey A. Morgan, MD

Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Presentation(s):

• Paper 22 - P10015/SARC033: A PHASE 2 TRIAL OF TRAMETINIB IN PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA

  Thursday, November 17, 2022
  1:48 PM – 1:56 PM